Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
IRBESARTAN
LABORATOIRE RIVA INC.
C09CA04
IRBESARTAN
300MG
TABLET
IRBESARTAN 300MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0131700003; AHFS:
APPROVED
2022-01-25
_RIVA-IRBESARTAN _ _Page 1 of 32_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR RIVA-IRBESARTAN Irbesartan Tablets 75 mg, 150 mg and 300 mg, Oral Manufacturer’s Standard Angiotensin II AT 1 Receptor Blocker LABORATOIRE RIVA INC. 660 Boul. Industriel Blainville, Quebec J7C 3V4 www.labriva.com Submission Control Number: 267377 Date of Initial Authorization: JAN 25, 2022 Date of Revision: OCT 6, 2022 _RIVA-IRBESARTAN _ _Page 2 of 32_ RECENT MAJOR LABEL CHANGES 1 INDICATIONS, 1.1 Pediatrics 08/2022 1 INDICATIONS, 1.2 Geriatrics 08/2022 7 WARNINGS AND PRECAUTIONS 08/2022 8 ADVERSE REACTIONS, 8.2 Clinical Trial Adverse Reactions 08/2022 8 ADVERSE REACTIONS, 8.5 Post-Market Adverse Reactions 08/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................................ 2 TABLE OF CONTENTS .......................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................................. 4 1 INDICATIONS ......................................................................................................................... 4 1.1 Pediatrics ............................................................................................................................... 4 1.2 Geriatrics ............................................................................................................................... 4 2 CONTRAINDICATIONS ............................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ........................................................................ 5 4 DOSAGE AND ADMINISTRATION ............................................................................................ 5 4.1 Dosing Consider Կարդացեք ամբողջական փաստաթուղթը